Document Detail

Exercise, Stress Resistance, and Central Serotonergic Systems.
MedLine Citation:
PMID:  21508844     Owner:  NLM     Status:  Publisher    
Voluntary exercise reduces the incidence of stress-related psychiatric disorders in humans and prevents serotonin-dependent behavioral consequences of stress in rodents. Evidence reviewed herein is consistent with the hypothesis that exercise increases stress resistance by producing neuroplasticity at multiple sites of the central serotonergic system which all help to limit the behavioral impact of acute increases in serotonin during stressor exposure.
Benjamin N Greenwood; Monika Fleshner
Related Documents :
6853914 - Hemodynamic, angiographic and scintigraphic correlates of positive exercise electrocard...
3549364 - Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-mont...
11459344 - Magnetocardiographic and electrocardiographic exercise mapping in healthy subjects.
9524014 - Therapeutic benefits of cilazapril in patients with syndrome x.
23805234 - Aerobic capacity, activity levels and daily energy expenditure in male and female adole...
19058604 - Survival of vibrio cholerae on different finger locations of a volunteer following arti...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-4-19
Journal Detail:
Title:  Exercise and sport sciences reviews     Volume:  -     ISSN:  1538-3008     ISO Abbreviation:  -     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-4-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375434     Medline TA:  Exerc Sport Sci Rev     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Integrative Physiology and Center for Neuroscience, University of Colorado-Boulder, Boulder, CO 80309-0354.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New treatment targets in ankylosing spondylitis and other spondyloarthritides.
Next Document:  Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension.